Floatz logo

(S)-2-(3-Methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-(2-(trifluoromethyl)pyrimidin-5-yl)pyridin-2-yl)propanamide

Osteoarthritis

Eli Lilly and CompanySmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Osteoarthritis cohort.

Asset / SponsorPhaseRating
Naltrexone
Brigham and Women's Hospital
Phase 4BBB
Buprenorphine
Mundipharma Pte Ltd.
Phase 4BBB
FENTANYL
Janssen Pharmaceutica
Phase 4BBB
Oxycodone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4BBB
Duloxetine
The Catholic University of Korea
Phase 4BBB

View all 48 →

Same molecule, other indications

(S)-2-(3-Methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-(2-(trifluoromethyl)pyrimidin-5-yl)pyridin-2-yl)propanamide is also rated in:

diabetic neuropathyDormant
B
Indicative ·
57 / 100
View asset →
diabetic neuropathyDormant
B
Indicative ·
57 / 100
View asset →
Osteo Arthritis KneeDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →